Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE CUSTOpharm, Inc.
SAN DIEGO, Jan. 31, 2014 /PRNewswire/ -- CUSTOpharm, Inc. is pleased to announce the creation of two specialty divisions focusing on the two primary focuses of the company since its inception. "The creation of the development and regulatory group as two free standing organizations will allow us to serve our customers better and focus on the ever changing landscape of the FDA," said Dave McCleary, President of the CUSTOpharm Development Company. The Development Company will reside within our 7,500 sq. ft. laboratory space in Carlsbad and continue to focus on the development of injectable products. The Regulatory Group is relocating to a new office in Del Mar. "Since the opening of our laboratories in 2012, we have experienced significant growth in both product development and regulatory. With the two specialty groups we will be able to continue growing and provide excellent services to our customers," said Fred Defesche, President of CUSTOpharm Regulatory Services.
About CUSTOpharm, Inc.
CUSTOpharm is a leading service provider in the areas of product development and regulatory affairs. The product development focuses on the development of generic injectable, nasal and ophthalmic dosage forms. The regulatory activities have pioneered and kept up with the ever changing regulatory landscape by transitioning to eCTD submissions in 2004 and moving to the gateway in 2008. The regulatory activities focus on submissions in the United States and Canada. We have filed more than 200 original applications and file more than 100 submissions per year. For more information, please visit http://www.custopharm.com.
©2012 PR Newswire. All Rights Reserved.